[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100612179":3},{"organization":4,"armGroups":7,"interventions":17,"overallOfficials":23,"centralContacts":24,"locations":30,"responsibleParty":61,"collaborators":63,"id":67,"slug":68,"hasResults":69,"nctId":70,"briefTitle":71,"officialTitle":72,"acronym":73,"eligibilityCriteria":74,"healthyVolunteers":75,"sex":76,"minAge":77,"maxAge":23,"enrollmentInfo":78,"targetDuration":23,"studyType":81,"phases":82,"briefSummary":84,"conditions":85,"keywords":87,"overallStatus":33,"whyStopped":23,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":100},{"fullName":5,"class":6},"Groupe Hospitalier de la Region de Mulhouse et Sud Alsace","OTHER",[8,13],{"label":9,"type":6,"description":10,"interventionNames":11},"AML","Elderly patients diagnosed with acute myeloid leukemia. An additional volume of blood (10 mL) and bone marrow (2 mL) will be collected during follow-up visits as part of their routine care.",[12],"Diagnostic Test: Epigenetic markers",{"label":14,"type":6,"description":15,"interventionNames":16},"Control group","Elderly patients scheduled for thoracic surgery involving sternotomy. A bone marrow sample (2 mL) will be obtained by sternal puncture in the operating room (after general anesthesia and before sternotomy), and an additional blood sample (10 mL) will be collected during the hospital stay.",[12],[18],{"type":19,"name":20,"description":21,"armGroupLabels":22,"otherNames":23},"DIAGNOSTIC_TEST","Epigenetic markers","Methylation profiles will be analyzed and DNA regions (CpG sites) that show significant differences between healthy and pathological cells from bone marrow will be identified. These regions could serve as epigenetic markers for cells from patients with LAM, if they can be used by digital PCR. These differentially methylated CpG islands will be targeted for the design of specific primer and probe pairs for use in digital PCR. The markers will then be tested in circulating free DNA from blood.",[9,14],null,[25],{"name":26,"role":27,"phone":28,"phoneExt":23,"email":29},"Bernard DRENOU, Dr","CONTACT","+33389646464","drenoub@ghrmsa.fr",[31,52],{"facility":32,"status":33,"city":34,"state":35,"zip":36,"country":37,"countryCode":38,"cosmosGeoPoint":39,"geoPoint":44,"contacts":45},"Groupe Hospitalier de la Région de Mulhouse et Sud Alsace","RECRUITING","Mulhouse","Alsace","68100","France","FR",{"type":40,"coordinates":41},"Point",[42,43],7.32866,47.75205,{"lat":43,"lon":42},[46,49],{"name":47,"role":27,"phone":48,"phoneExt":23,"email":29},"Bernard Drénou, MD","+33389647755",{"name":50,"role":51,"phone":23,"phoneExt":23,"email":23},"Gheorghe Gavra, MD","SUB_INVESTIGATOR",{"facility":53,"status":33,"city":34,"state":23,"zip":36,"country":37,"countryCode":38,"cosmosGeoPoint":54,"geoPoint":56,"contacts":57},"GHRMSA",{"type":40,"coordinates":55},[42,43],{"lat":43,"lon":42},[58,60],{"name":59,"role":27,"phone":28,"phoneExt":23,"email":29},"Bernard DRENOU, MD",{"name":50,"role":51,"phone":23,"phoneExt":23,"email":23},{"type":62,"investigatorFullName":23,"investigatorTitle":23,"investigatorAffiliation":23,"oldNameTitle":23,"oldOrganization":23},"SPONSOR",[64],{"name":65,"class":66},"Institut de Recherche en Hématologie et Transplantation (IRHT)","UNKNOWN","100612179","determination-of-epigenetic-markers-of-acute-myeloblastic-leukemia-in-elderly-patients-100612179",false,"NCT07250217","Determination of Epigenetic Markers of Acute Myeloblastic Leukemia in Elderly Patients","Collection of Biological Samples for Research Purposes: Determination of Epigenetic Markers of Acute Myeloblastic Leukemia in Elderly Patients","LAMME","1. \u002F Control Group\n\n   Inclusion Criteria:\n   * Age ≥ 60 years;\n   * Scheduled for cardiac surgery involving sternotomy;\n   * Normal blood count within the two months preceding sampling;\n   * Affiliated with, or beneficiary of, a social security system;\n   * Written informed consent to participate in the study.\n\n   Exclusion Criteria:\n   * Patients deemed unsuitable for sampling by the surgeon performing the procedure;\n   * Patients under legal protection measures;\n   * Patients under judicial supervision or deprived of liberty by judicial or administrative decision;\n   * Presence of positive virological markers indicating active infection (hepatitis B, hepatitis C, or HIV).\n2. \u002F AML Group\n\nInclusion Criteria:\n\n* Age ≥ 60 years;\n* Diagnosis of de novo AML or AML secondary to myelodysplastic syndrome, scheduled to receive azacitidine-based treatment;\n* Affiliated with, or beneficiary of, a social security system;\n* Written informed consent to participate in the study.\n\nExclusion Criteria:\n\n* Diagnosis of a hematologic disease other than AML;\n* Clinical signs suggestive of active central nervous system leukemia, or presence of isolated extramedullary leukemia;\n* Previous treatment for AML other than hydroxyurea;\n* Severe comorbidities that could interfere with the study, as assessed by the principal investigator;\n* Presence of positive virological markers indicating active infection (hepatitis B, hepatitis C, or HIV);\n* Patients under legal protection;\n* Patients under judicial supervision or deprived of liberty by judicial or administrative decision.",true,"ALL","60 Years",{"count":79,"type":80},30,"ESTIMATED","INTERVENTIONAL",[83],"NA","The main objective of this study is to identify epigenetic markers specific to abnormal myeloid cells in patients with acute myeloid leukemia (AML) by analyzing the methylation of circulating cell-free DNA in plasma.",[86],"Acute Myeloblastic Leukemia",[86,88,20,89,90],"Methylome","Bone marrow","Diagnosis","2026-02-03",{"date":93,"type":94},"2026-02-04","ACTUAL",{"date":96,"type":94},"2026-01-13",{"date":98,"type":80},"2027-12-01",{"name":5,"class":6},2]